Bio Total Stockholder Equity vs Short Term Debt Analysis
BIO Stock | USD 325.58 1.89 0.58% |
Bio Rad financial indicator trend analysis is way more than just evaluating Bio Rad Laboratories prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bio Rad Laboratories is a good investment. Please check the relationship between Bio Rad Total Stockholder Equity and its Short Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Total Stockholder Equity vs Short Term Debt
Total Stockholder Equity vs Short Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bio Rad Laboratories Total Stockholder Equity account and Short Term Debt. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Bio Rad's Total Stockholder Equity and Short Term Debt is 0.19. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Bio Rad Laboratories, assuming nothing else is changed. The correlation between historical values of Bio Rad's Total Stockholder Equity and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Bio Rad Laboratories are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Total Stockholder Equity i.e., Bio Rad's Total Stockholder Equity and Short Term Debt go up and down completely randomly.
Correlation Coefficient | 0.19 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Short Term Debt
Most indicators from Bio Rad's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bio Rad Laboratories current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. At this time, Bio Rad's Sales General And Administrative To Revenue is very stable compared to the past year. As of the 22nd of November 2024, Enterprise Value is likely to grow to about 1 B, while Selling General Administrative is likely to drop about 481.6 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 1.6B | 1.6B | 1.4B | 769.3M | Total Revenue | 2.9B | 2.8B | 2.7B | 1.4B |
Bio Rad fundamental ratios Correlations
Click cells to compare fundamentals
Bio Rad Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bio Rad fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 8.0B | 13.0B | 17.8B | 13.5B | 12.3B | 12.9B | |
Short Long Term Debt Total | 439.8M | 14.1M | 11.0M | 1.2B | 1.4B | 1.5B | |
Other Current Liab | 158.5M | 354.0M | 404.9M | 312.2M | 301.6M | 316.6M | |
Total Current Liabilities | 905.5M | 631.5M | 680.9M | 568.7M | 522.8M | 338.4M | |
Total Stockholder Equity | 5.8B | 9.9B | 13.7B | 9.6B | 8.7B | 9.2B | |
Property Plant And Equipment Net | 701.2M | 693.5M | 695.8M | 679.6M | 723.7M | 759.9M | |
Net Debt | (220.9M) | (648.1M) | (459.8M) | 764.0M | 1.0B | 1.1B | |
Retained Earnings | 5.5B | 9.3B | 13.5B | 9.9B | 9.3B | 9.7B | |
Cash | 660.7M | 662.2M | 470.8M | 434.2M | 404.0M | 257.1M | |
Non Current Assets Total | 5.8B | 10.8B | 15.8B | 10.3B | 9.3B | 9.7B | |
Non Currrent Assets Other | (997.7B) | (2.1T) | (3.1T) | (1.8T) | 96.4M | 101.2M | |
Cash And Short Term Investments | 1.1B | 996.7M | 875.5M | 1.8B | 1.6B | 1.7B | |
Net Receivables | 392.7M | 419.4M | 423.5M | 494.6M | 489.0M | 272.4M | |
Common Stock Shares Outstanding | 30.2M | 30.2M | 30.2M | 29.8M | 29.2M | 29.1M | |
Liabilities And Stockholders Equity | 8.0B | 13.0B | 17.8B | 13.5B | 12.3B | 12.9B | |
Non Current Liabilities Total | 1.3B | 2.5B | 3.4B | 3.3B | 3.0B | 3.2B | |
Inventory | 554.0M | 622.3M | 572.2M | 719.3M | 780.5M | 819.5M | |
Other Current Assets | 113.3M | 97.5M | 124.8M | 153.3M | 171.7M | 92.3M | |
Other Stockholder Equity | 371.6M | 329.5M | 335.4M | 183.9M | (183.5M) | (174.3M) | |
Total Liab | 2.3B | 3.1B | 4.1B | 3.9B | 3.6B | 3.7B | |
Property Plant And Equipment Gross | 701.2M | 1.5B | 1.5B | 1.5B | 1.8B | 1.9B | |
Total Current Assets | 2.2B | 2.1B | 2.0B | 3.2B | 3.0B | 3.2B | |
Accumulated Other Comprehensive Income | (87.3M) | 282.5M | (175.6M) | (466.8M) | (336.0M) | (319.2M) | |
Short Term Debt | 426.2M | 38.3M | 36.9M | 36.8M | 40.9M | 33.9M | |
Accounts Payable | 287.1M | 139.5M | 141.9M | 135.0M | 144.6M | 116.6M | |
Intangible Assets | 145.5M | 199.5M | 253.9M | 332.1M | 320.5M | 188.7M | |
Other Assets | 40.3M | 13K | 82K | 94.6M | 85.1M | 71.4M | |
Long Term Debt | 13.6M | 12.3M | 10.5M | 1.2B | 1.2B | 1.3B | |
Good Will | 264.1M | 291.9M | 347.3M | 406.5M | 413.6M | 339.1M | |
Treasury Stock | (38.4M) | (99.9M) | (106.3M) | (263.6M) | (237.2M) | (225.4M) | |
Property Plant Equipment | 499.3M | 491.4M | 695.8M | 498.6M | 573.4M | 371.9M | |
Current Deferred Revenue | 33.7M | 42.5M | 50.9M | 52.2M | 35.8B | 37.5B | |
Other Liab | 1.2B | 2.4B | 3.4B | 2.0B | 2.3B | 2.4B | |
Short Term Investments | 459.5M | 334.5M | 404.7M | 1.4B | 1.2B | 1.3B | |
Net Tangible Assets | 5.8B | 9.9B | 13.1B | 9.2B | 10.6B | 11.1B | |
Retained Earnings Total Equity | 5.5B | 9.3B | 13.5B | 9.9B | 11.4B | 12.0B | |
Capital Surpluse | 410.0M | 429.4M | 441.7M | 447.5M | 514.6M | 366.5M | |
Deferred Long Term Liab | 997.8M | 2.1B | 3.1B | 1.8B | 2.0B | 2.1B |
Pair Trading with Bio Rad
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bio Rad position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio Rad will appreciate offsetting losses from the drop in the long position's value.Moving against Bio Stock
0.46 | FBRX | Forte Biosciences Trending | PairCorr |
0.42 | VALN | Valneva SE ADR Downward Rally | PairCorr |
0.42 | VCNX | Vaccinex | PairCorr |
The ability to find closely correlated positions to Bio Rad could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bio Rad when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bio Rad - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bio Rad Laboratories to buy it.
The correlation of Bio Rad is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bio Rad moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bio Rad Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bio Rad can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.412 | Earnings Share (28.06) | Revenue Per Share 90.815 | Quarterly Revenue Growth 0.028 | Return On Assets 0.0186 |
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.